Apellis Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) has announced its participation in the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 10:50 a.m. ET. The presentation will be delivered by co-founder and CEO Cedric Francois, M.D., Ph.D., and can be accessed live via webcast on the company's website. A replay will be available for 90 days post-event. Apellis focuses on developing targeted therapies that address debilitating diseases linked to complement cascade activation, including hematology and ophthalmology.

News Market Reaction – APLS

+1.81%

+1.81% Session move

In the trading session that priced this news, APLS gained 1.81%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. ET. The conference will be held in a virtual meeting format.

The presentation will be given by Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, and will be available live via webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at https://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com.

Investor Contact:
Argot Partners
apellis@argotpartners.com
+1 212.600.1902

FAQ

When will Apellis Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

Apellis Pharmaceuticals will present on January 12, 2021, at 10:50 a.m. ET.

Who will present for Apellis Pharmaceuticals at the conference?

Cedric Francois, M.D., Ph.D., co-founder and CEO of Apellis Pharmaceuticals, will present.

How can I access the Apellis Pharmaceuticals presentation?

The presentation will be available live via webcast on Apellis' 'Events and Presentations' page on their website.

Will there be a replay of the Apellis Pharmaceuticals presentation?

Yes, a replay of the webcast will be available for 90 days after the event.

What are the key areas Apellis Pharmaceuticals focuses on?

Apellis Pharmaceuticals develops therapies targeting diseases related to complement cascade activation, including hematology and ophthalmology.